Sanofi Reports Uninspiring Q4 Sales Amid Skepticism On Dupixent’s COPD Potential
Revenues Fall Short Of Consensus
The French firm’s Q4 sales missed consensus due to a slow-down in its vaccine franchise, while analyst concern regarding a pivotal readout for blockbuster product Dupixent in COPD increased.
